CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma). According to GlobalData, Phase II drugs for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CMN-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CMN-005 overview
CoImmune overview
CoImmune is a biopharmaceutical company that carries out the development and manufacture of immunotherapies to treat cancer, inflammatory and autoimmune diseases. Its clinical products pipeline includes CARCIK-CD19 (CMN-005), CAR-CIK (CMN-006), CAR-CIK solid tumors, and CMN-001. The comnpany’s products are used in the treatment of acute lymphoblastic leukemia, non-hodgkin’s lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and metastatic renal cell carcinoma, among others. It also carries out the research and development activities through its cell therapy technology platforms which include allogeneic cytokine-induced killer (CIK) and autologous RNA-loaded dendritic cells. CoImmune is headquartered in Durham, North Carolina, the US.
For a complete picture of CMN-005’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
